Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/33380
Title: | Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: Results of a phase I study. | Authors: | Briggs P. ;Brettell M.;Juneja S.;Wolf M.;Januszewicz E.H.;Richardson G.;Scarlett J.;Prince H.M.;Rischin D.;Toner G.C.;Seymour J.F.;Blakey D.;Gates P.;Eerhard S.;Chapple P.;Quinn M. | Institution: | (Prince, Rischin, Toner, Seymour, Blakey, Gates, Eerhard, Chapple, Quinn, Brettell, Juneja, Wolf, Januszewicz) Blood and Marrow Transplant Service, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Vic., Australia (Richardson, Scarlett, Briggs) Department of Medical Oncology and Clinical Haematology, Monash Medical Centre, Melbourne, Vic., Australia | Issue Date: | 20-Oct-2012 | Copyright year: | 2000 | Publisher: | Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom) | Place of publication: | United Kingdom | Publication information: | Bone Marrow Transplantation. 26 (9) (pp 955-961), 2000. Date of Publication: 2000. | Abstract: | This phase I study was designed to determine the optimal dosages of a novel repetitive high-dose therapy regimen for patients with metastatic breast cancer (MBC). The planned treatment was three cycles of high-dose cyclophosphamide, thiotepa and docetaxel delivered every 35 days with progressive dose-escalation in successive cohorts. Each cycle was supported by peripheral blood progenitor cells (PBPC) and filgrastim. Eighteen patients were entered into this trial. Of the planned 54 treatment cycles, 44 were delivered and 11 patients completed all three cycles. The dose-limiting toxicities were interstitial pneumonitis and mucositis with moderately severe diarrhea (n = 3) and rash (n = 3). There were no treatment-related deaths. Of the 17 patients with evaluable disease, 16 patients responded with six patients achieving a complete remission and an additional four patients achieving no detectable disease (negative restaging including PET scan) but a persistently abnormal bone scan. At a median follow-up of 12 months, median progression-free survival was 11 months with the median overall survival not reached. The recommended doses for phase II/III studies are cyclophosphamide (4 g/m2), thiotepa (300 mg/m2) and docetaxel (100 mg/m2). | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1038/sj.bmt.1702650 | PubMed URL: | 11100274 [http://www.ncbi.nlm.nih.gov/pubmed/?term=11100274] | ISSN: | 0268-3369 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/33380 | Type: | Article | Type of Clinical Study or Trial: | Observational study (cohort, case-control, cross sectional or survey) |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.